When Japanese pharmaceutical company Daiichi Sankyo Co. discovered a groundbreaking cancer treatment, it turned to bigger Western drugmaker AstraZeneca Plc. to help commercialize the therapy that ...

AstraZeneca PLC AZN and partner Merck MRK announced that the Japanese Ministry of Health, Labour, and Welfare has approved their PARP inhibitor, Lynparza for an early-stage breast cancer indication.

TOKYO, Jan 29 (Reuters) - AstraZeneca Plc (AZN.L), opens new tab will file for Japanese approval of its COVID-19 vaccine as early as mid-February, the Yomiuri newspaper reported, making it the ...

TOKYO (MarketWatch) -- AstraZeneca Plc AZN aims to further accelerate efforts to bring its drugs to the Japanese market by investing more and expanding clinical studies, company executives said ...

AstraZeneca has raised its bet on Japan's drug market by buying out the remaining stake held by Sumitomo Chemical in its Japanese unit AstraZeneca K.K. The British group said on Wednesday the ...

AstraZeneca PLC AZN announced that the Japanese regulatory authority has granted marketing approval to Lokelma (sodium zirconium cyclosilicate) for the treatment of patients with hyperkalaemia in ...

Japan has become one of the hot drug markets, and Johnson & Johnson has decided to partner up with AstraZeneca to take its hot cancer drug abiraterone acetate (Zytiga ...

Beyfortus (nirsevimab), a single-dose monoclonal antibody developed and commercialized in partnership by AstraZeneca (NASDAQ:AZN) and Sanofi (NASDAQ:SNY), has been approved in Japan for the ...

Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.

(RTTNews) - AstraZeneca (AZN.L, AZN) said that the Japanese Ministry of Health, Labour and Welfare approved Koselugo (selumetinib) for the treatment of paediatric patients three years of age and ...